Osteoporosis Postmenopausal
📧 Sign up to get email alerts when something new happens for Osteoporosis Postmenopausal.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Kauliv (teriparatide) — Strides Pharma (Cyprus) Limited
Kauliv (teriparatide) has been authorised by the EMA for osteoporosis-related indications, including postmenopausal osteoporosis, by Strides…
-
EMA approval · 2026-08-24EMA Authorised: Izamby (denosumab) — Mabxience Research SL
EMA authorises Izamby (denosumab) for bone resorption disorders including osteoporosis and postmenopausal osteoporosis.
-
EMA approval · 2026-08-20EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.
Authorisation of Junod (denosumab) by Gedeon Richter Plc. for conditions related to bone resorption and osteoporosis, including postmenopaus…
-
EMA approval · 2026-08-19EMA Authorised: Prolia (denosumab) — Amgen Europe B.V.
EMA authorises Prolia (denosumab) for osteoporosis-related indications, confirming market approval in the European Union.
-
EMA approval · 2026-08-18EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Conexxence (denosumab) for osteoporosis indications, including postmenopausal osteoporosis and bone resorption conditions.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-17EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
The EMA has authorised Kefdensis (denosumab) by Stada Arzneimittel AG for conditions related to bone resorption and osteoporosis, including …
-
EMA approval · 2026-07-14EMA Authorised: Acvybra (denosumab) — Reddy Holding GmbH
EMA authorised Acvybra (denosumab) for osteoporosis-related indications in Europe, with Reddy Holding GmbH as MAH.
-
EMA approval · 2026-06-16EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
Authorised status for Kefdensis (denosumab) by Stada Arzneimittel AG for bone resorption disorders including osteoporosis and postmenopausal…
-
EMA approval · 2026-02-20EMA Authorised: Osqay (denosumab) — Theramex Ireland Limited
EMA has authorised Osqay (denosumab) by Theramex Ireland Limited for a bone resorption indication, marking approval in the European Union.
-
EMA approval · 2024-11-25EMA Authorised: Kauliv (teriparatide) — Strides Pharma (Cyprus) Limited
The EMA has authorized Kauliv, a teriparatide-containing medicine by Strides Pharma (Cyprus) Limited, for osteoporosis and postmenopausal os…
-
EMA approval · 2024-08-28EMA Authorised: Ibandronic Acid Teva (ibandronic acid) — Teva Pharma B.V.
EMA authorised Teva's ibandronic acid with indications including postmenopausal osteoporosis, breast neoplasms, neoplasm metastasis, and bon…
-
FDA approval · 2018-06-27FDA Approved: EVISTA — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for EVISTA (raloxifene hydrochloride) by Eli Lilly. The action updates the labeling with a new o…
-
FDA approval · 2016-04-08FDA Approved: RALOXIFENE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved the original application for raloxifene hydrochloride (Amneal Pharmaceuticals LLC) as a generic, for postmenopausal osteoporosi…